The timing of initiation of SGLT2 inhibitors is particularly important, as most of the studies added it toward the end of hospitalization (within 10 to 14 days of hospitalization), as in patients with type 2 diabetes, SGLT2 inhibitors are often withheld during the early days of hospitalization due to concerns about volume depletion, hypotension, and euglycemic ketoacidosis[37,38]. Here, SLC5A2 is linked to type 2 diabetes mellitus.